A new duet in cancer biology: AMPK the typical and UBE2O the atypical. (4th May 2017)

• Record Type: Journal Article
• Authors: Vila, Isabelle K.; Song, Su Jung; Song, Min Sup
• Is Part Of: Molecular & cellular oncology. Volume 4:Number 3(2017)
• Publication Date: 2017-05-04
• Subjects: AMPK -- AMPKα2 -- arsenite -- breast cancer -- cancer metabolism -- HIF1α -- mTOR -- prostate cancer -- UBE2O -- ubiquitination; Tumors -- Periodicals; Neoplasms; Periodicals; 616.99
• DOI: 10.1080/23723556.2017.1304846
• Languages: English
• ISSNs: 2372-3556

Abstract

ABSTRACT: Ubiquitin-conjugating enzyme E2O ( UBE2O ) is upregulated in human cancers. We have demonstrated that genetic deletion or pharmacological blockade of UBE2O reduces tumorigenesis through inhibiting the mammalian target of rapamycin complex 1–hypoxia-inducible factor 1-α pathway. Critically, UBE2O targets adenosine monophosphate (AMP)-activated protein kinase-α 2 (AMPKα2) for ubiquitination and degradation. We thus suggest the UBE2O-AMPKα2 axis as a potential therapeutic target for cancer.